SCI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
SCI is not a strong buy right now for a beginner long-term investor with $50,000-$100,000, but it is still a reasonable hold/watch rather than a sell. The technical setup is constructive, options sentiment is mildly bullish, and analysts remain positive despite small target cuts. However, the lack of a fresh buy signal from Intellectia, no recent news catalyst, and notable congressional selling make this a less compelling immediate entry for an impatient buyer.
SCI is in a short-term uptrend. Price closed at 78.56, above the pivot at 75.093 and near resistance at R2 79.394, which suggests momentum is positive but the stock is approaching a technical ceiling. MACD histogram is positive and expanding, reinforcing bullish momentum. RSI_6 at 75.059 indicates the stock is stretched near overbought territory, so upside may continue but the current level is not an especially attractive fresh entry. Moving averages are converging, which suggests a transition phase rather than a clean, powerful trend. The nearby support zone is 77.752 and 75.093, while deeper support sits at 72.434.
Analysts still rate the stock positively, with JPMorgan maintaining Overweight and UBS maintaining Buy. The stock also shows favorable technical momentum, with a positive and expanding MACD histogram. Options flow is bullish, and the historical pattern data suggests a positive near-term drift. SCI also has no negative news over the past week, which helps keep sentiment stable.
Congress members made 6 trades in the last 90 days, all sales and no purchases, which is a bearish signal from influential market participants. There were no reported politician purchases. No recent news in the last week means there is no near-term catalyst to drive a strong rerating.
No usable latest-quarter financial snapshot was provided, so I cannot assess the most recent quarterly growth trends. The latest quarter season is not available in the data.
Wall Street remains constructive on SCI. JPMorgan lowered its price target to $100 from $110 and kept an Overweight rating, while UBS lowered its target to $93 from $95 and kept a Buy rating. This is a mildly positive analyst setup, but the recent target cuts show a slightly softer outlook than before. Overall, pros still favor the stock, while the main con is that expectations have been trimmed.
